Enteromix, Russia's cancer vaccine achieves 100% efficancy in clicinal trials

Russia’s Enteromix, a personalized mRNA-based cancer vaccine, has shown 100% efficacy and safety in clinical trials, shrinking tumors and halting their growth without serious side effects. Developed by Russia’s National Medical Research Radiology Centre and the Engelhardt Institute of Molecular Biology, it uses four harmless viruses to train the immune system to target cancer cells. Trials with 48 volunteers showed tumor reductions of 60-80% and improved survival rates. The vaccine, initially targeting colorectal cancer, has variants in development for brain cancer and melanoma. Enteromix awaits final regulatory approval and, if authorized, could revolutionize cancer treatment by offering a safer, personalized alternative to chemotherapy and radiation.
*This news was published by the Times of India on September 10, 2025.*

 

 

 

Source Click